Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, 450 Brookline Avenue, Boston, MA 02215, USA.
Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, 450 Brookline Avenue, Boston, MA 02215, USA.
Hematol Oncol Clin North Am. 2019 Apr;33(2):233-248. doi: 10.1016/j.hoc.2018.12.003. Epub 2019 Jan 17.
Radiotherapy has known immunomodulatory effects and there exists a strong preclinical rationale for combining radiotherapy with immunotherapies. Broadly, the concurrent administration of immunotherapies and radiotherapy does not seem to result in undue toxicity, even when radiotherapy is administered to definitive doses. Recently reported results from prospective clinical trials evaluating radiotherapy/ICB combinations, such as the PACIFIC trial, provide important information on safety and efficacy in the definitive setting and identify potential abscopal effects. This review details the preclinical foundation for the combination of radiotherapy and immunotherapies, summarizes the most recent clinical data available, and highlights active and future areas of study.
放疗具有已知的免疫调节作用,并且有强有力的临床前理论基础支持将放疗与免疫疗法相结合。一般来说,放疗与免疫疗法联合应用似乎不会导致过度毒性,即使放疗剂量达到根治性剂量。最近报道的前瞻性临床试验评估了放疗/免疫检查点抑制剂联合治疗的结果,如 PACIFIC 试验,为根治性治疗中的安全性和疗效提供了重要信息,并确定了潜在的远隔效应。本文详细介绍了放疗与免疫疗法联合应用的临床前基础,总结了目前最新的临床数据,并强调了当前和未来的研究领域。